A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.

Clinical trial NCT07623642 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07623642
Sponsor: GV20 Therapeutics
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Uterine Cervical Neoplasms Triple Negative Breast Neoplasms Prostatic Neoplasms Squamous Cell Carcinoma of Head and Neck Esophageal Squamous Cell Carcinoma Cholangiocarcinoma Gallbladder Neoplasms Colorectal Neoplasms Pancreatic Ductal Adenocarcinoma Carcinoma, Non-Small-Cell Lung Small Cell Lung Carcinoma

Start date: 2026-06-02
Primary completion: 2028-06-15
Enrollment: 227

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.